3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Specimen Handling
53
pembrolizumab
51
Carboplatin
51
Magnetic Resonance Spectroscopy
46
Pemetrexed
41
Cisplatin
36
Paclitaxel
25
durvalumab
24
osimertinib
22
Nivolumab
22
Gemcitabine
20
Radiosurgery
18
Radiotherapy
17
Docetaxel
17
atezolizumab
15
Immunoglobulin G
15
Biopsy
15
Disulfides
14
130-nm albumin-bound paclitaxel
13
Taxes
12
Radiation
12
Educational Status
12
Etoposide
11
Blood Specimen Collection
11
Early Intervention, Educational
10
Drug Therapy
10
Practice Guidelines as Topic
9
Platinum
9
Methods
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled